. Optimizing phase II of drug development for disease-modifying compounds. Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S15-20. PubMed.

Recommends

Please login to recommend the paper.

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

No Available Comments